Ascentage Pharma Group International’s (AAPG) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reissued their buy rating on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research report sent to investors on Thursday morning,Benzinga reports. BTIG Research currently has a $48.00 price objective on the stock.

Several other equities analysts also recently weighed in on the company. Oppenheimer started coverage on Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price on the stock. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Finally, Rodman & Renshaw assumed coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company’s stock. Based on data from MarketBeat, Ascentage Pharma Group International presently has a consensus rating of “Buy” and a consensus price target of $48.00.

Ascentage Pharma Group International Stock Performance

AAPG stock opened at $21.34 on Thursday. Ascentage Pharma Group International has a 52 week low of $17.56 and a 52 week high of $48.45. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53. The firm has a 50-day simple moving average of $24.10 and a 200-day simple moving average of $29.99.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $24.72 million for the quarter.

Hedge Funds Weigh In On Ascentage Pharma Group International

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UBS Group AG grew its holdings in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares in the last quarter. XY Capital Ltd boosted its position in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the last quarter. Tema Etfs LLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter valued at about $610,000. Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International during the second quarter worth about $391,000. Finally, Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International during the third quarter worth about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.